C4 Therapeutics Rg

Clinical‑stage biopharma C4 Therapeutics develops MonoDAC/BiDAC protein‑degrader drugs; lead Cemsidomide is Phase 1/2 for multiple myeloma/NHL, with BRAF V600 and EGFR LUCA candidates, backed by Roche, Biogen, Merck, and Calico.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 110
HQ: Watertown

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CCCC	C4 Therapeutics Rg Cap: 0.2B	EQUITY	NMS	USD	US12529R1077	Active	📈